GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Enovis Corp (NYSE:ENOV) » Definitions » 10-Year RORE %

ENOV (Enovis) 10-Year RORE % : 180.51% (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Enovis 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Enovis's 10-Year RORE % for the quarter that ended in Dec. 2024 was 180.51%.

The industry rank for Enovis's 10-Year RORE % or its related term are showing as below:

ENOV's 10-Year RORE % is ranked better than
97.13% of 418 companies
in the Medical Devices & Instruments industry
Industry Median: 0.455 vs ENOV: 180.51

Enovis 10-Year RORE % Historical Data

The historical data trend for Enovis's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enovis 10-Year RORE % Chart

Enovis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.69 30.81 -26.37 -73.07 180.51

Enovis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -73.07 -99.55 -127.76 -185.83 180.51

Competitive Comparison of Enovis's 10-Year RORE %

For the Medical Devices subindustry, Enovis's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enovis's 10-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Enovis's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Enovis's 10-Year RORE % falls into.


;
;

Enovis 10-Year RORE % Calculation

Enovis's 10-Year RORE % for the quarter that ended in Dec. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -14.29-4.05 )/( -10.16-0 )
=-18.34/-10.16
=180.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2024 and 10-year before.


Enovis  (NYSE:ENOV) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Enovis 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Enovis's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enovis Business Description

Traded in Other Exchanges
Address
2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Executives
John Kleckner officer: Principal Accounting Officer 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Berry Phillip Benjamin (ben) officer: SVP, Chief Financial Officer 2711 CENTERVILLE ROAD SUITE 400, WILMINGTON DE 19808
Rajiv Vinnakota director 8730 STONY POINT PARKWAY, SUITE 150, RICHMOND VA 23235
A Clayton Perfall director
Brady Shirley officer: EVP, Colfax, Pres. & CEO, DJO 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Patricia A Lang officer: SVP, Chief HR Officer C/O DIEBOLD NIXDORF, INCORPORATED, 5995 MAYFAIR ROAD, NORTH CANTON OH 44720
Bradley J Tandy officer: SVP, General Counsel P.O. BOX 587, 56 E. BELL DRIVE, WARSAW IN 46580
Daniel A Pryor officer: SVP??Strategy & Business Deve. DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Matthew L. Trerotola director, officer: President & CEO 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Christopher M Hix officer: SVP, Chief Financial Officer 2160 SATELLITE BLVD., SUITE 200, DULUTH GA 30097
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Christine Ortiz director 1200 ABERNATHY ROAD, NE, SUITE 1200, ATLANTA GA 30328
Angela S Lalor director 3M CENTER, BLDG. 0220-09-E-02, ST PAUL MN 55144 1000
Shyam Kambeyanda officer: ESAB President and SVP, Colfax 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Douglas J. Pitts officer: Controller, PAO 100 MATSONFORD ROAD, RADNOR PA 19087